

XX S
SHEET 1 OF 3

FORM PTO - 1449

INFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: LEX-004

APPLICANT(S): Gillies

SERIAL NO.: 09/292,217

FILING DATE: April 15, 1999 GROUP: 1645

U.S. PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
FH	AA	4,196,265	4/1/80	Koprowski <i>et al.</i>	435	2	
	AB	4,816,567	3/28/89	Cabilly <i>et al.</i>	530	387	
	AC	5,225,539	7/6/93	Winter	530	387.3	
	AD	5,541,087	7/30/96	Lo <i>et al.</i>	435	697	
	AE	5,585,089	12/17/96	Queen <i>et al.</i>	424	133.1	
	AF	5,650,150	7/22/97	Gillies	424	134.1	
	AG	5,726,044	3/10/98	Lo <i>et al.</i>	435	69.7	
	AH	5,733,876	3/31/98	O'Reilly <i>et al.</i>	514	12	
	AI	5,837,682	11/17/98	Folkman <i>et al.</i>	514	12	
	AJ	5,854,205	12/29/98	O'Reilly <i>et al.</i>	514	2	
	AK	5,885,795	3/23/99	O'Reilly <i>et al.</i>	435	69.1	

FOREIGN PATENT DOCUMENTS

EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG Y/N

OTHER ART, JOURNAL ARTICLES, ETC.

EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
FH	CA	Arenberg <i>et al.</i> (1996) "Interferon- γ -inducible Protein 10 (IP-10) Is an Angiostatic Factor That Inhibits Human Non-small Cell Lung Cancer (NSCLC) Tumorigenesis and Spontaneous Metastases," J. EXP. MED. 184:981-992.
FH	CB	Barnett <i>et al.</i> (1994) "Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system," BIOCHIMICA ET BIOPHYSICA ACTA 1209:130-139.

EXAMINER

Form 1449

DATE CONSIDERED

6/12/00

O I P E J
OCT 01 1999

SHEET 2 OF 3


FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT		ATTORNEY DOCKET NO.: LEX-004 APPLICANT(S): Gillies SERIAL NO.: 09/292,217 FILING DATE: April 15, 1999 GROUP: 1646
OTHER ART, JOURNAL ARTICLES, ETC.		
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
FI	CC	Brooks <i>et al.</i> (1994) "Integrin $\alpha_v\beta_3$ Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels," <i>CELL</i> 79:1157-1164.
	CD	D'Amato <i>et al.</i> (1994) "Thalidomide is an inhibitor of angiogenesis," <i>PROC. NATL. ACAD. SCI. USA</i> 91:4082-4085.
	CE	Gasson <i>et al.</i> (1984) "Purified Human Granulocyte-Macrophage Colony-Stimulating Factor: Direct Action on Neutrophils," <i>SCIENCE</i> 226:1339-1342.
	CF	Gillies <i>et al.</i> (1989) "High-level expression of chimeric antibodies using adapted cDNA variable region cassettes," <i>J. OF IMMUNOLOGICAL METHODS</i> 125:191-202.
	CG	Gillies <i>et al.</i> (1992) "Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells," <i>PROC. NATL. ACAD. SCI. USA</i> 89:1428-1432.
	CH	Gillies <i>et al.</i> (1998) "Antibody-IL-12 Fusion Proteins Are Effective in SCID Mouse Models of Prostate and Colon Carcinoma Metastases," <i>J. OF IMMUNOL.</i> 160:6195-6203.
	CI	Gillis <i>et al.</i> (1978) "T Cell Growth Factor: Parameters of Production And A Quantitative Microassay for Activity," <i>J. OF IMMUNOL.</i> 6:2027-2032.
	CJ	Huck <i>et al.</i> (1986) "Sequence of a human immunoglobulin gamma 3 heavy chain constant region gene: comparison with the other human C γ genes," <i>NUCLEIC ACIDS RESEARCH</i> 14:1779-1789.
	CK	Huse <i>et al.</i> (1989) "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," <i>SCIENCE</i> 246:1275-1281.
	CL	Jones <i>et al.</i> (1986) "Replacing the complementarity-determining regions in a human antibody with those from a mouse," <i>NATURE</i> 321:522-525.
	CM	Ingber <i>et al.</i> (1990) "Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth," <i>NATURE</i> 348:555-557.
	CN	Kang <i>et al.</i> (1991) "Antibody redesign by chain shuffling from random combinatorial immunoglobulin libraries," <i>PROC. NATL. ACAD. SCI. USA</i> 88:11120-11123.
	CO	LaVallie <i>et al.</i> (1993) "Cloning and Functional Expression of a cDNA Encoding the Catalytic Subunit of Bovine Enterokinase," <i>J. OF BIOLOGICAL CHEMISTRY</i> 268:23311-23317.
EXAMINER	<i>Tom Hornsby</i>	DATE CONSIDERED 6/12/00



SHEET 3 OF 3

FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT		ATTORNEY DOCKET NO.: LEX-004 APPLICANT(S): Gillies SERIAL NO.: 09/292,217 FILING DATE: April 15, 1999 GROUP: 1646
OTHER ART, JOURNAL ARTICLES, ETC.		
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)	
FH	CP	Lo <i>et al.</i> (1998) "High level expression and secretion of Fc-X fusion proteins in mammalian cells," PROTEIN ENGINEERING 11:495-500.
	CQ	Lode <i>et al.</i> (1998) "Natural Killer Cell-Mediated Eradication of Neuroblastoma Metastases to Bone Marrow by Targeted Interleukin-2 Therapy," BLOOD 91:1706-1715.
	CR	Maloney <i>et al.</i> (1994) "Phase I Clinical Trial Using Escalating Single-Dose Infusion of Chimeric Anti-CD20 Monoclonal Antibody (IDE-C2B8) in Patients with Recurrent B-Cell Lymphoma," BLOOD 84:2457-2466.
	CS	Mestre <i>et al.</i> (1997) "Retinoids Suppress Epidermal Growth Factor-induced Transcription of cyclooxygenase-2 in Human Oral Squamous Carcinoma Cells," CANCER RESEARCH 57:2890-2895.
	CT	Nedwin <i>et al.</i> (1985) "Human lymphotxin and tumor necrosis factor genes structure, homology and chromosomal localization," NUCLEIC ACIDS RESEARCH 6:6361-6373.
	CU	O'Reilly <i>et al.</i> (1994) "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma," CELL 79:315-328.
	CV	O'Reilly <i>et al.</i> (1997) "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth," CELL 88:277-285.
	CW	Perez <i>et al.</i> (1989) "Isolation and Characterization of a cDNA Encoding the KS1/4 Epithelial Carcinoma Marker," J. OF IMMUNOLOGY 142:3662-3667.
	CX	Riethmuller <i>et al.</i> (1994) "Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma," THE LANCET 343:1177-1183.
	CY	Taniguchi <i>et al.</i> (1983) "Structure and expression of a cloned cDNA for human interleukin-2," NATURE 302:305-309.
	CZ	Varki <i>et al.</i> (1984) "Antigens Associated with a human lung adenocarcinoma defined by monoclonal antibodies," CANCER RESEARCH 44:681-687.
	CAA	Verhoeyen <i>et al.</i> (1988) "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," SCIENCE 239:1534-1536.
	CAB	Xiang <i>et al.</i> (1997) "Elimination of Established Murine Colon Carcinoma Metastases by Antibody-Interleukin 2 Fusion Protein Therapy," CANCER RESEARCH 57:4948-4955.
EXAMINER	<i>Some H. m...</i>	
	DATE CONSIDERED	<i>6/12/00</i>

FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO.: LEX-004 APPLICANT(S): Gillies SERIAL NO.: 09/292,217 FILING DATE: April 15, 1999 GROUP: 1646					
U.S. PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME		CLASS	SUB CLASS	FILING DATE IF APPROPRIATE	
FI	AL	5,543,297	8/6/96	Cromlish <i>et al.</i>		435	25		
	AM	5,886,178	3/23/99	Allen <i>et al.</i>		544	238		
	AN	5,667,776	09/16/97	Zimmerman <i>et al.</i>		424	85.1		
FOREIGN PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG Y/N
FW	BA	WO 92/08495	05/29/92	PCT					Y
	BB	WO 98/00127	01/08/98	PCT					Y
	BC	EP 706 799 A3	04/17/96	EP					Y
	BD	WO 89/09620	10/19/89	PCT					N
	BE	WO 92/02240	02/20/92	PCT					Y
	BF	WO 97/15666	05/01/97	PCT					Y
OTHER ART, JOURNAL ARTICLES, ETC.									
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)								
FI	CAC	Eisenthal, (1990) "Indomethacin up-regulates the generation of lymphokine-activated killer-cell activity and antibody-dependent cellular cytotoxicity mediated by interleukin-2," <i>Cancer Immunol. Immunotherap.</i> 31:342-348.							
	CAD	LeBerthon <i>et al.</i> (1991) "Enhanced Tumor Uptake of Macromolecules Induced by a Novel Vasoactive Interleukin 2 Immunoconjugate," <i>Cancer Research</i> 51:2694-2698.							
	CAE	Abstract XP-002116766, "Prostaglandins, their inhibitors and cancer" from <i>Prostaglandins, Leukotrienes and Essential Fatty Acids</i> (1996) 54(2): 83-94.							
EXAMINER	<i>Fiona Horan</i>			DATE CONSIDERED		<i>6/12/00</i>			

FORM PTO - 1449 INFORMATION DISCLOSURE STATEMENT 					ATTORNEY DOCKET NO.: LEX-004 APPLICANT(S): Gillies SERIAL NO.: 09/292,217 FILING DATE: April 15, 1999 GROUP: 1646				
U.S. PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE		
FOREIGN PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG Y/N
OTHER ART, JOURNAL ARTICLES, ETC.									
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)								
FH	CAF	Gillies <i>et al.</i> (1999) "Improving the Efficacy of Antibody-Interleukin 2 Fusion Proteins by Reducing Their Interaction with Fc Receptors," CANCER RESEARCH 59:2159-2166.							
EXAMINER	<i>Form H-2m/mt</i>			DATE CONSIDERED 6/12/00					